SHARE NOW
Leading clinical-stage biopharmaceutical company IN8bio, Inc. has presented compelling data at the Society for Neuro-Oncology (SNO) 28th Annual Meeting. The data showcased the success of their innovative gamma-delta (γδ) T cell therapy, INB-200. All patients completing mandated doses surpassed a progression-free survival (PFS) of seven months, with one patient achieving 28.5+ months without progression.
INB-200 is a genetically modified autologous Drug Resistant Immunotherapy (DRI) product candidate for the treatment of solid tumors. The novel platform utilizes genetic engineering to generate chemotherapy-resistant gamma delta T cells which can be administered concurrently with standard-of-care treatment in solid tumors.
The current standard-of-care regimen for newly diagnosed glioblastoma (GBM) consists of primary resection, six weeks of chemoradiation therapy followed by six cycles of maintenance monthly temozolomide therapy.
The Phase I trial assesses the safety and preliminary efficacy of the addition of DeltEx DRI gamma-delta T cells to standard-of-care maintenance therapy. The trial assesses three different dosing regimens from a single dose delivered on cycle 1 day 1 in Cohort 1, to three doses delivered on day 1 of cycles 1-3 in Cohort 2, to finally six doses delivered on day 1 of cycles 1-6 in Cohort 3. All patients receive 1×107 cells per dose, however, the number of doses varies depending on the cohort of enrollment.
How are you enjoying this news article? Let us know your thoughts, here >>
“Every patient in the Phase I trial that completed the mandated doses has exceeded the standard-of-care median progression-free survival of four to seven months, with one patient in Cohort 2 remaining alive and progression-free past 28.5 months following three doses,” said Trishna Goswami, MD, Chief Medical Officer at IN8bio.
- All patients completing mandated doses surpassed a PFS of seven months.
- One patient with an IDH-mutant glioma remains alive and progression-free at 28.5+ months.
- No treatment-related serious adverse events were reported across all cohorts.
- Common treatment-emergent adverse events were mostly Grade 1-2 toxicities related to standard-of-care temozolomide.
- Preserved gamma-delta T cells were found 148 days after the initial infusion, indicating the durability of the therapy.
- The groundbreaking data positions INB-200 as a potential game-changer in GBM treatment, offering improved outcomes beyond the current standard of care.
“We are excited by the safety and efficacy results across cohorts in this study and look forward to dosing additional patients with the added hope of improving their treatment outcomes,” continued Goswami. “Following up on our oral presentation at this year’s ASCO Annual Meeting, these encouraging results demonstrate the early promise of IN8bio’s DeltEx DRI gamma-delta T cells for treating GBM patients and potentially other solid tumor cancers.”
Source: IN8bio Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
